[Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy]. / Enfermedad de Morquio (mucopolisacaridosis IV-A): aspectos clínicos, diagnósticos y nuevo tratamiento con terapia de reemplazo enzimático.
Arch Argent Pediatr
; 113(4): 359-64, 2015 Aug.
Article
en Es
| MEDLINE
| ID: mdl-26172013
ABSTRACT
Mucopolysaccharidosis type IV-A (Morquio A disease) is an autosomal recessive lysosomal storage disease caused by mutations in the gene encoding the N-acetylgalactosamine-6-sulfate sulfatase, that results in impaired catabolism of two glycosaminoglycans, chondroitin-6-sulfate and keratan sulfate. Clinical presentations reflect a spectrum of progression from a severe phenotype to an attenuated expression. Accumulation of substrate manifests predominantly as short stature and skeletal dysplasia, including atlantoaxial instability and cervical cord compression. Other abnormalities in the visual, auditory, cardiovascular and respiratory systems can also affect individuals with Morquio disease. Elosulfase alfa showed in clinical trials in children and adults a significant and sustained improvement in endurance and urinary levels of keratan sulfate. Data from the ongoing observational, multinational Morquio A Registry Study will provide valuable information on the long-term efficacy and safety of elosulfase alfa in patients, as well as on the natural history of this very rare disease.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Condroitinsulfatasas
/
Mucopolisacaridosis IV
/
Terapia de Reemplazo Enzimático
Tipo de estudio:
Diagnostic_studies
Límite:
Child, preschool
/
Humans
Idioma:
Es
Año:
2015
Tipo del documento:
Article